Immunotherapy targeting isoDGR-protein damage extends lifespan in a mouse model of protein deamidation.

Autor: Kalailingam P; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Mohd-Kahliab KH; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Ngan SC; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., Iyappan R; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., Melekh E; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., Lu T; iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China., Zien GW; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Sharma B; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Guo T; iMarker Lab, Westlake Laboratory of Life Sciences and Biomedicine, Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, China., MacNeil AJ; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., MacPherson RE; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., Tsiani EL; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., O'Leary DD; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada., Lim KL; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore., Su IH; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Gao YG; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore., Richards AM; Department of Cardiology, National University Heart Centre, Singapore, Singapore.; Department of Cardiology, University of Otago, Christchurch, New Zealand., Kalaria RN; Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK., Chen CP; Memory, Aging and Cognition Centre, National University Health System, Singapore, Singapore., McCarthy NE; Centre for Immunobiology, The Blizard Institute, Bart's and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Sze SK; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.; Department of Health Sciences, Faculty of Applied Health Sciences, Brock University, St. Catharines, ON, Canada.

Publikováno v: EMBO molecular medicine [EMBO Mol Med] 2023 Dec 07; Vol. 15 (12), pp. e18526. Date of Electronic Publication: 2023 Nov 16.

Safety and tumour hypoxia modifying effect of buparlisib with radiotherapy in NSCLC: a phase I dose escalation study

Autor: Skwarski, M, McGowan, DR, Bradley, KM, Fenwick, JD, Gleeson, FV, Horne, A, Maughan, T, McKenna, WG, Mohammed, S, Muschel, RJ, Ng, SM, Panakis, N, Strauss, VY, Stuart, R, Vallis, KA, Macpherson, RE, Higgins, GS

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::4b61327300ded5319490815dbd631f2b
https://doi.org/10.1016/j.jtho.2018.08.888

Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients.

Autor: Bourigault P; Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK., Skwarski M; Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.; Department of Clinical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK., Macpherson RE; Department of Radiology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., Higgins GS; Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK.; Department of Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK., McGowan DR; Department of Oncology, University of Oxford, Oxford, OX3 7DQ, UK. daniel.mcgowan@oncology.ox.ac.uk.; Department of Medical Physics and Clinical Engineering, Oxford University Hospitals NHS Foundation Trust, Oxford, UK. daniel.mcgowan@oncology.ox.ac.uk.

Publikováno v: EJNMMI research [EJNMMI Res] 2021 Dec 29; Vol. 11 (1), pp. 130. Date of Electronic Publication: 2021 Dec 29.

Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer.

Autor: Skwarski M; Department of Oncology, University of Oxford, Oxford, England, United Kingdom.; Department of Oncology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., McGowan DR; Department of Oncology, University of Oxford, Oxford, England, United Kingdom.; Radiation Physics and Protection, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Belcher E; Department of Cardiothoracic Surgery, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Di Chiara F; Department of Cardiothoracic Surgery, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Stavroulias D; Department of Cardiothoracic Surgery, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., McCole M; Department of Cellular Pathology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Derham JL; Department of Oncology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Chu KY; Department of Oncology, University of Oxford, Oxford, England, United Kingdom.; Department of Oncology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Teoh E; Department of Oncology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Chauhan J; Ludwig Institute for Cancer Research Oxford, University of Oxford, Oxford, England, United Kingdom., O'Reilly D; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Harris BHL; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Macklin PS; Nuffield Department of Medicine, University of Oxford, Oxford, England, United Kingdom., Bull JA; Wolfson Centre for Mathematical Biology, University of Oxford, Oxford, England, United Kingdom., Green M; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Rodriguez-Berriguete G; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Prevo R; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Folkes LK; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Campo L; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Ferencz P; Institute of Biomedical Engineering, University of Oxford, Oxford, England, United Kingdom., Croal PL; Institute of Biomedical Engineering, University of Oxford, Oxford, England, United Kingdom., Flight H; Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Qi C; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom., Holmes J; Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom., O'Connor JPB; Division of Cancer Sciences, University of Manchester, Manchester, England, United Kingdom., Gleeson FV; Department of Radiology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., McKenna WG; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Harris AL; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Bulte D; Institute of Biomedical Engineering, University of Oxford, Oxford, England, United Kingdom., Buffa FM; Department of Oncology, University of Oxford, Oxford, England, United Kingdom., Macpherson RE; Department of Radiology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom., Higgins GS; Department of Oncology, University of Oxford, Oxford, England, United Kingdom. geoffrey.higgins@oncology.ox.ac.uk.; Department of Oncology, Oxford University Hospitals National Health Service Foundation Trust, Oxford, England, United Kingdom.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 May 01; Vol. 27 (9), pp. 2459-2469. Date of Electronic Publication: 2021 Feb 17.

Verification of the effect of data-driven brain motion correction on PET imaging.

Autor: Odagiri, Hayato^1,2 (AUTHOR) hayato.odagiri.e2@tohoku.ac.jp, Watabe, Hiroshi³ (AUTHOR), Takanami, Kentaro² (AUTHOR), Akimoto, Kazuma¹ (AUTHOR), Usui, Akihito¹ (AUTHOR), Kawakami, Hirofumi⁴ (AUTHOR), Katsuki, Akie⁴ (AUTHOR), Uetake, Nozomu⁴ (AUTHOR), Dendo, Yutaka⁵ (AUTHOR), Tanaka, Yoshitaka⁵ (AUTHOR), Kodama, Hiroyasu⁵ (AUTHOR), Takase, Kei² (AUTHOR), Kaneta, Tomohiro^1,2 (AUTHOR)

Publikováno v: PLoS ONE. 7/5/2024, Vol. 19 Issue 7, p1-15. 15p.